Preliminary DMT therapy data will guide the decision to initiate a phase 2 trial in the U.S. in early 2024. The post Cybin Lands Key U.S....
Reset Pharma is specifically honing in on the plight of cancer patients. The post Reset Pharma Licenses Filament Drug to Combat Demoralization in Cancer...
AWAKN-P001 Is a N-methyl-D-aspartate Receptor-Modulating Drug Used in Combination with Psycho-Social Support for The Treatment of Severe Alcohol Use Disorder...
Will PharmaTher be the next company to get a psychedelic medicine to market? The post PharmaTher Submits New Drug Application to the FDA appeared first...
The newly granted U.S. patent covers deuterated 5-methoxy-dimethyltryptamine (5-MeO-DMT) analogs. The post Cybin Granted U.S. Patent for 5-MeO-DMT appeared...
Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety Psychedelics biotech Cybin (NYSE: CYBN) and UK-based Small...
Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed. The post News...
Many experts have been predicting some big mergers and acquisitions in the psychedelic industry. Well, it looks like they were spot on. This week has...
Functional mushroom company Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) following the company’s release of its unaudited financials for the quarter...
Reset Pharma has licensed Filament’s botanical psilocybin drug candidate for a phase 2 clinical trial studying demoralization syndrome Filament Health...